Discounted Cash Flow
Akari Therapeutics Plc. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | $-18.1m | $-24.7m | — | — |
| 2017 | — | $-35.4m (-95.1%) | $-31.6m (-28.2%) | — | — |
| 2018 | — | $-16.5m (53.5%) | $-22.6m (28.6%) | — | — |
| 2019 | — | $-17.1m (-3.9%) | $-12.9m (42.8%) | — | $-0.01 |
| 2020 | — | $-17.1m (0.1%) | — | — | $-0.01 (0.0%) |
| 2021 | — | $-17.4m (-2.0%) | — | — | $0.00 (100.0%) |
| 2022 | — | $-17.7m (-1.9%) | — | — | $0.00 |
| 2023 | — | $-10.0m (43.6%) | $-16.4m | — | $0.00 |
| 2024 | — | $-19.8m (-97.8%) | $-12.6m (23.6%) | — | $0.00 |
| 2025 | — | $-17.3m (12.6%) | $-10.6m (15.8%) | — | $0.00 |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.